EUROPEAN HOSPITAL DUSSELDORF 14 NOVEMBER, WEDNESDAY

ISSUE: MEDICAL, SPECIAL



Welcome to the **Future with TRUMPF**

Experience the pioneering innovations specially developed for OR and ICU.



TruSystem 7500 The new premium generation of operating tables



TruVidia HD The first HD camera in an operating light

ContrastLine Innovative lighting technology for intra-operative imaging



Medical technology

) ME

TECHNICAL, PHARMACEUTICAL, INDUSTRIAL NEWS & MUCH MORE

Trends towards miniaturisation and digitisation will continue, says ZVEI

As in past years, this year's MEDICA is one of the most important stages for the medical technology industry. International manufacturers will do a song and dance to dazzle the international clientele. As Managing Director of the German Electrical and



Hans-Peter Bursig. Managing Director of ZVEI

Electronic Manufacturers' Association (Deutscher Zentralverband Elektrotechnikund Elektronikindustrie e.V. – ZVEI), Hans-Peter Bursig, is well aware of this trade fair's role for the export-oriented med-tech companies, particularly those in Germany. In an interview with Meike Lerner, of European Hospital, he highlighted the position and perspectives of German medical technology firms and the fair's significance for the domestic med-tech industry.

'Medical technology is certainly one of the most important groups of exhibitors at MEDICA, be it in terms of space – four halls are dedicated exclusively to this segment - or of visitors. In visitors' surveys, for years medical technology has been named among the top-ranking points of interest,' Hans-Peter Bursig pointed out. 'Last year's trends will no doubt continue for years to come: miniaturisation and digitisation. The products are becoming increasingly compact and the importance of software and the electronic components to control these products is growing. It also

means that the products become more modular and this can be combined into complex systems that are tailored to the customer's needs and specifications. European Hospital: How well are

German medical technology companies positioned internationally?

H-P B: The German medical technology industry is very well positioned, internationally as well as in Europe. Depending on your point of view, German manufacturers rank number one to three. In Europe, we are no WE WANT TO THANK OUR 950 CUSTOMERS FOR NOT SETTLING FOR LESS THAN THE PACS THEY REALLY NEED

NOVEMBER 2007

Visit us at Medica Hall 15, Booth 15G20



continued on page 2

Visit us at Medica 2007 • Hall 9 • Stand D41

Snap open for quality. Snap closed for protection.

Aquasonic[®] 100, the world standard for medical ultrasound, now has a new proprietary Snap-Cap[™] with valve, providing unparalleled benefits to both user and patient.

Designed for One Handed Operation:Engineered to Eliminate Drips and "Draw Back."

Exclusive self-sealing silicone valve instantly cuts off the flow of gel.

Eliminates drawing product back into the bottle, thus reducing the potential for cross-contamination


Maintains a clean and safe work environment by preventing

AmbientLine Revolutionary lighting concept for intensive care, recovery and operating theatre

Visit us at Medica 2007 Hall 13, Stand A42

www.trumpf-med.com





drips and product residue

Provides precise unimpeded flow control from the new larger aperture and valve

Easy to use One-Handed Snap-Cap keeps the nozzle and aperture protected from the work environment.

Open and close the cap with one hand and maintain position and procedure continuity

Protect the nozzle from old gels that can often collect on the surface of ultrasound equipment

AND no more lost red tips thanks to the permanently attached cap

> Welcome our new Snap-Cap to your practice... Invite a safer and more efficient workplace.



NEWS

continued from page 1

doubt the leading country. Internationally, we are behind the US, nevertheless German companies do well on the US market. However, Germany is no longer the international lead-market for medical technology. We have to bring innovative products to the domestic market much faster. If we fail to do so, we will run the risk of losing our competitive edge.

For German companies, MEDICA has developed into a platform from which they face up to international competition – only on the German market. Today, this is the internationally leading fair where customers compare German companies with their international competitors. For the German medical technology industry, which heavily relies on export, it is an enormous advantage to have the major fair right on the doorstep.

What do you expect from this year's MEDICA?

H-P B: The prime task of such fairs is to network, to maintain contacts as well as initiate new business. Over the last few years, MEDICA has done well in this respect. German customers have displayed increased interest in innovative products and their potential to improve efficiency and quality. Thus, this trade fair is also an indicator of the investment climate in Germany.

Which products and technologies offer the most potential for German med-tech firms?

H-P B: In general, German medical technology is strong in the capital goods sector, where quality and service during the entire life cycle play a crucial role. Today, modern healthcare and the cost-efficient operation of hospitals and doctors' offices are inconceivable without these products. The capital goods sector is complemented by IT solutions and problem-specific packages for defined clinical issues. German medical technology is also well positioned in the market for efficiencyand quality-enhancing solutions.

CONGRESSES & EVENTS Wednesday 14 November 2007

MEDICA CONGRESS 14:30-17:30 CCD Pavilion, 1st floor, room 17

MRSA – an interdisciplinary problem

• MRSA in in-patient nursing of geriatrics, by Violets Lorecka, Kassel

• Hygiene measurements and epidemiology during occurrence of MRSA, by Dr. Markus

Schimmelpfennig, Kassel • Pharmaco-therapy for MRSA: possibilities and limitations, by Dr. Hans-Walter Schmitt, Kassel

MEDICA MEDIA WORKSHOP 14:00-16:00 Hall 16, booth A 05, workshop room

TeleHomecare – Do nursing robots offer new possibilities? Chairman: Dr Pablo Mentzinis, BITKOM, Berlin

MEDICA PLUS 12:00-13:00

Hall 1, 1st floor, room 111 EPC/RFID and barcode in action – for your transparent healthcare supply chain. Organiser: GS1 Germany GmbH

MEDICA VISION 11:00-13:00 Hall 3, booth H 92

Diagnostics and therapy

perspectives: new imaging developments

• Conceptual changes in oncology triggered by molecular imaging, Prof. Dr. Ottmar Schober, Uniklinik Münster

• From molecule to routine cardiac diagnostics, Prof. Dr. Dr. Wolfgang Bauer, Uniklinik Würzburg

 Sonohistologie – a histological procedure for ultrasound characterisation of tissue, Prof. Dr. Helmut Ermert, Ruhr-Universität-Bochum

• US-guided navigated intervention, Prof. Dr. Martin Overhoff, FH Gelsenkirchen

• 3-D ultrasound imaging in navigated orthopaedic surgery, Prof. Dr. Georg Schmitz, Ruhr-

Universität BochumRadiology in the third millennium, Prof. Dr. Hans-Peter Meinzer,

Deutsches Krebsforschungszentrum Heidelberg

13:00 - 14:00

Hall 3, booth H 92

Diagnostics and therapy perspectives: new developments in cardiology

• Monitoring chronic heart insufficiency: development of a pulmonary implant , Prof. Dr. Thomas Schmitz-Rode, RWTH Aachen


• Vital sensor networks for close monitoring of patients with an acute cardinal risk constellation, Christian Hofmann, Fraunhofer IIS, Erlangen

• From cell biology to health services research in cardiology, Prof. Georg Ertl,

Universitätsklinikum Würzburg • Aortic stenosis: new possibilities of percutaneous aortic valve replacement, PD Dr. Stefan Sack, Universitätsklinkum Essen

COMPAMED

13:25 - 16:30
Hall 8a, booth G 40
COMPAMED Forum 'High-tech for Medical Devices'
Applied Nanotechnology: from







Nonin Medical, Inc. 13700 1st Avenue North Plymouth, MN 55441 USA Phone: +1.763.553.9968 Toll Free: 800.356.8874 Fax: +1.763.553.7807 www.nonin.com MedAir AB Fibervägen 2 82450 Hudiksvall Sweden Phone: +46 653 717979 Fax: +46 653 717980 www.medair.se

experimental approaches to real products, Dr. med Rainer Hanselmann, sarastro GmbH • Nano2Life: a landmark in EU nanobiotechnology, Dr. Klaus-M. Weltring, Gesellschaft für Bioanalytik-Muenster e.V., Münster • Transponder-based microsystems for medical applications, Dr. Uwe Schnakenberg, RWTH Aachen • Creating value through intellectual assets, Dr. Robert Harrison, Sonnenber Fortmann Patent- & Rechtsanwälte, München • European micro/nano atlas for medical devices, Dr. Uwe Kleinkes, IVAM Research, Dortmund • Application of plastic in medical technology - an overview: Torsten Urban, Kunststoff-Institut Lüdenscheid, Lüdenscheid



©2007 Nonin Medical, Inc. All trademarks are the property of Nonin Medical, Inc or MedAir AB unless otherwise noted

Switzerland - An Artificial Organ Centre for Biomedical Engineering Research has been set up at the University of Bern, drawing together its established areas of expertise in medical technology.

Housed in the university's Medical Faculty, the ARTORG Centre is active in interdisciplinary teaching and research and development, focusing especially on artificial organs. Research groups from units within the Medical Faculty and other faculties at the University of Bern and other university institutions and universities of applied sciences will work together in the new centre.

Medical technology has become an established highprofile discipline in the University of Bern's Strategy 2012. The importance and excellent international reputation of Bernese medical technology is based on the traditionally high standards of Bern's teaching hospitals, its contribution to the National Centre of Competence in Research Co-Me, the Technology for Humans research focus programme at the Bern University of Applied Sciences (BFH) and the commercially successful medical technology companies in the Espace region of central Switzerland.

Close co-operation between clinicians, technologists, and industry

According to Martin Täuber, Dean of the Medical Faculty, this new platform will coordinate existing projects and clinical approaches that involve

NEW WiFi **Messenger for** hospital use

The WiFi Messenger system from CLB International

CLB International BV (Netherlands) has designed the WiFi Messenger (CLB-WMG) specifically for use in the healthcare sector. The firm reports that this well-designed, robust device works on any existing wireless (LAN) infrastructure nabling full duplex communication via speech or video. The device may also be used for data transfer. The WiFi Messenger features a dual display, freely programmable buttons, multiple alarm types, location detection, a telephone book and speech recognition. CLB also offers other IP solutions for healthcare - including a nurse call system, which is able to report alarms from different medical devices and has been certified in accordance with the European Guidelines for Medical Devices (CE 0344).

New medical technology centre to target artificial organs • Blood vessels

artificial organs and medical technology, yield improved technological support and cross-fertilization of projects. The scientific programme of the ARTORG Centre will be established and implemented by 11 newly created assistant professorships. The research groups will focus on the following artificial organs and specialist areas:

- Bladder • Ear
- Eye
- Heart
- Kidney
- Liver
- Lung Pancreas
- Spine
- Implantation



technology of artificial organs

Medical technology research and development at the ARTORG Centre will involve close cooperation between clinicians, technologists, the medical technology industry and other Swiss technology institutions. In particular, the centre will work closely with the Technology and IT Faculty of Bern University of Applied Sciences. The ARTORG Centre's involvement in the

programme and PhD programme of the Graduate School for Cellular and Biomedical Sciences will generate additional synergies between research and teaching. The Director of the Institute for Surgical Technologies and Biomechanics at the Medical Faculty is responsible for the operational management of the centre. A scientific committee appointed by the university management is responsible for the strategic leadership of the ARTORG Centre and also for the quality of its science. Details: http://www.unibe.ch

Personal. Powerful. Pocket.

NEWS

specialist Master of Science in

Biomedical Engineering degree

We focus on offering real solutions in ultrasound. Whether it is application versatility across the broadest range of patient types, superior imaging quality for more confident and accurate diagnosis, or advanced technologies and ergonomic system design that improves your clinical workflow, you can always expect the best clinical support.

Answers for life.





A presentation for the 31st trinational DEGUM, ÖGUM, and SGUM conference in Leipzig, Germany, by Axel Feldkamp MD (below), Chairman of the DEGUM paediatrics division, and Director of the paediatrics department at Duisburg Hospital

ANOD

Neonata Cvstic -ibrosis Diagnosis

The World Leader Macroduct/Sweat-Chek

The unsurpassed sweat collection and analysis technologies of Macroduct® and Sweat-Chek[™] are trusted in thousands of labs and clinics worldwide to deliver reliable sweat testing for excluding or confirming Cystic Fibrosis.

Nanoduct

4

Now this gold standard method for sweat testing has been combined and miniaturized for the tiny limbs of newborn infants with Wescor's new Nanoduct[®]. Nanoduct is truly

The advantages of ultrasound for paediatric diagnosis



ltrasound is the most important imaging technique in paediatrics - more so than in any other branch of medicine. This is attributable to a number of factors. X-ray exposure is a more significant risk factor for paediatric patients than for adults by virtue of the cumulative nature of X-ray dosages, thus making paediatric patients more likely to receive a higher dose of radiation. Moreover, some types of immature tissue are more susceptible to radiation. Thus it is essential to avoid the use of Xrays in children and young adults. Ultrasound scanners have now evolved to the point where the

image quality they deliver obviates the need to use any other imaging technology. Various types of heart catheterisation can now be realised using ultrasound in lieu of radiography. Elaborate highradiation imaging procedures for the urinary tract are increasingly replaced by the use of ultrasound contrast media. Complex imaging of skull pathology in paediatric patients can now be realised using ultrasound rather than radiography.

Another advantage of ultrasound examinations lies in their ready availability. In neonatology in particular, examinations of neonates in incubators are indispensable, since moving the child from one place to another, wrapped in a textile, would constitute an extreme risk. In addition, thanks to the progressive miniaturisation of ultrasound scanners, paediatric ultrasound examinations can be realised pretty much anywhere and at any time.

High resolution ultrasound scanner heads (ideal for neonatology by virtue of their relatively shallow penetration depth) often produce image quality

that is unmatched by any other method. In some cases, only ultrasound can detect congenital heart defects, brain morphology defects, cranial bleeding, and haemodynamic complications. Although MRI provides outstanding image quality in infants, the examinations are lengthy and an infant must be either anaesthetised or heavily sedated.

Ultrasound is taught in paediatric training programs owing to the extreme usefulness of the technique. Consequently, ultrasound is widely available and can be used for screening purposes. For example, the current practice of doing a hip screening for all newborns has reduced to a minimum the number of hip defects requiring surgery.

Thus ultrasound can be regarded as the paediatric imaging technique of choice for the following reasons:

- the child is not exposed to radiation
- ultrasound devices can be deployed just about anywhere
- ultrasound image quality constantly improves, thanks to the use of high-resolution transducers

ACCUVIX **High-end system applies** premium technology from Medison's proven brand

NEW

The advanced ultrasound system ACCUVIX XQ has been widely recognised worldwide for its advanced technology and stability, but a new ultrasound system is about to steal its thunder.' its manufacturer reports

diagnosis of Cystic Fibrosis

See Us at MEDICA Booth #3F26

For More information: CALL • 800 453 2725 • 435 752 6011 WEB • WWW.Wescor.com/biomedical EMAIL • biomed@wescor.com



Produced by MEDISON Co Ltd (CEO: J. B. Choi) Accuvix XQ was ranked, according to the Klein Report, in second place in the number of units sold in 2005 as well as 2006 in the US\$200 million American obstetrics and gynaecology ultrasound market. The XQ has now been superseded by the latest in the line: the Accuvix V10.

'The brand new Accuvix V10 integrates various proven technologies from the existing Accuvix line,' said Mr Oh, project leader of V10 in the Medison R&D department. 'However, this unit upgrades accuracy and efficiency with new technologies, while optimising user convenience with its ergonomic design.'

The V10's high definition 17" LCD monitor provides optimised resolution of 2-D, 3-D and 4-D image quality. The V10 has various built-in





A highly portable mini-ultrasound device



n emergencies, the first few minutes are vital, and having an ultrasound device for initial diagnosis could prove lifesaving. Speaking of a new portable ultrasound device from Siemens Medical Solutions Klaus Hambüchen, head of the Ultrasound group of Siemens Medical Solutions, said: 'This multifunctional system helps medical personnel to make the right decision within that time frame.' Although the portable device to which he refers — the Acuson P10 – was designed specially for acute care, e.g. in the ICU, an ambulance or medic flights, it is also suitable as a



functions enabling speed and accuracy. Users can save images and re-view them with ease, enabling more efficient management of patients and effective diagnoses, Medison adds. 'Accuvix V10 offers quality of Barely bigger than your BlackBerry and weighing just 500 grams diagnostic tool in the first hour in cardiac emergency care, but the company adds that it is also suitable for surgery, in obstetrics/gynaecology or in veterinary medicine.

'As an additional diagnostic device, Acuson P10 supplements initial examinations in emergency medicine comparable to a visual stethoscope. When needed, nursing staff or paramedics can perform the initial important examination in the emergency ward. Acuson P10 is used primarily to triage patients. This ensures that each patient receives the treatment necessary according to the seriousness of the illness or injuries sustained within a shorter time period than before,' Siemens reports. The device will go on sale this year, with its black & white screen, but an additional version (still pending) will have a color Doppler function. Special lithium ion accumulators enable continuous scanning for about one hour.

Images from the Acuson P10 can be stored in the Hospital Information System (HIS).

see it all •••• MEDISON

Visit us at MEDISON Booth Booth B60, Hall 9 Duesseldorf Trade Exhibition Centre

Global Launching!

Your Clearest View Within

performance and ease of use to clinicians in a range of fields, including, but not limited to, obstetrics, gynaecology, radiology, cardiology and urology.'

Medison, based in Seoul, Korea, was founded in 1985 and pioneered the first commercial real-time 3-D ultrasound scanner. Today the firm manufactures specialised diagnostic ultrasound systems ranging from portable to digital 3-D and 4-D, and has sales offices in more than 100 countries. *Contact: MEDISON Co Ltd, Binie Kim/Marketing Dept. Telephone: 02-2194-1092 E-mail. Bini99@medison.com Corporate and product information: www.medison.com.* Meet the ACCUVIX V10, combining futuristic stateof-the-art technology and outstanding user-interface design. The new ACCUVIX V10 contains cutting-edge 2D, 3D and 4D image technologies: Dynamic MR[™], SRF (Speckle Reduction Filter)[™], 3D XI[™], and VOCAL[™]. The innovative system platform ensures optimal patient throughput. A 17-inch flat-panel display, set on an articulating arm, delivers superb operator convenience and high-resolution images.



YOUR CLEAREST VIEW WITHIN
www.medison.com | marketing@medison.com

MEDISON, winner of 2007 Frost & Sullivan Competitive Strategy Leadership Award







ENTHERMICS FLUID & BLANKET WARMING CABINETS



- Electro-Thermal cable provides radiant, convecting & conductive heating.
- Units vary from 12 liter / 0.06 cu.meter to 42 liters / 0.6 cu.meter capacity.
- Heating range: 32C to 94C.
- Electronic controls, Alarms, Security locking system, interior lights, automatic energy saving shut down.

IMPACT INSTRUMENTATION

First affordable Portable Ventilator designed for mass casualty care: 73X



- Up to 11 hours of continuous on 02
- No pressure cycling, no auto cycling
- No position sensitivity
- No wasting of precious oxygen
- Rechargeable battery pack
- Comprehensive alarm system
- Digital airway pressure gauge and battery charge indicator
- Inexpensive ventilator circuits
- Used with/without HEPA or Chemical Bio filters

FDA certified.

SHIELDING INTERNATIONAL



Secure yourself with their full line of x-ray Protective apparel and accessories

ARMSTRONG MEDICAL CARTS



- Lightweight Aluminum construction
 Easy accessory attachments
 - High quality swivel casters

World's 1st Cardiac motion evaluation in minutes

Toshiba's new Artida Ultrasound system is the world's first ultrasound system that can track and display myocardial wall motion three-dimensionally. 'I can obtain several parameters in just a few minutes — longitudinal strain, radial strain, circumferential strain, rotation, shear, twist and torsion of every cardiac segment,' confirmed **Leopoldo Pérez de Isla MD PhD FESC**, of the Cardiovascular Imaging Unit in the Cardiovascular Institute at the Clínico San Carlos Hospital, Madrid.

The system has a wall motion tracking feature that allows the user to obtain angle-independent, quantitative and regional information about myocardial contraction.

3-D Speckle

This new diagnostic tool was designed to improve case assessments. Dr Pérez explained its value: 'The heart has three dimensions, so heart motion does also happen in three dimensions. So far we can assess wall motion quantitatively only two-dimensionally, not taking the complex twist and shear motion of the heart muscle into account. The new 3-D-speckle technology (developed by Toshiba) allows us to follow speckle in three spatial directions. What's more, the acquisition and analysis of the data sets is easy and fast, using the 3-D data set. The new technology provides a fast and global approach to the analysis of these parameters and avoids its under-use due to the time consuming 2-D derived speckle technology.' Therefore, arbitrary views of the heart



The Sarano digital US

The Sarano digital, black and white ultrasound system, made by Shimadzu, is on show at MEDICA. The company reports: 'This all-round system ombines the latest in hardware, software and probe technology, generating high-performance imaging quality as well as improving the digital handling of clinical data. The Sarano is suitable for hospital use and private practice – for stationary as well as ambulant applications. A large number of medical fields, such as radiology, internal medicine,

urology, gynaecology and obstetrics will benefit from this economical and efficient instrument.'

High-res images

The core technology for the improved transmission quality and accurate display of the ultrasound image data is the newly developed digital beam former with DBT technology. 'It processes and transmits data ten times faster without any noise. In this way, even the most delicate tissue structures can be shown through highresolution ultrasound images.' In addition the system includes microimaging array technology for a maximum frequency of 15 MHz. The five-tier fine-tuning of the probe frequency and consequently the diagnosis-specific settings bothcontribute to the improved images, the maker points out. 'Tissue Harmonic Imaging (THI) increases the spot and contrast resolution in the B-mode under difficult diagnostic conditions. Fast image iteration frequencies, focusing on the pixel level as well as high image dynamics, further increase authentication and diagnostic confidence.



The system also offers a wide range of lightweight, high-resolution electronic probes, and is said to be ideal for ambulant and stationary applications



6

- (2 locking & I tracking) • Stabilizing frame with bumper
- Double wall construction
- Ball bearing drawer slides
- Durable powder paint

Visit us at Medica, Hall 16 stand D40-8

Ask us about our show specials!

ISO 9001 FDA Certified Servicing a Worldwide distributor network in 70+ countries. J D Honigberg International, Inc. Fax: I – 847 412 0034 (USA) • E-Mail: medical@jdhintl.com www.jdhmedical.com







Dr Leopoldo Pérez

that are unavailable in 2-D imaging can be obtained for surgical planning.

Additional features

Artida's new SmartCore engine employs with the processing power of more than 80 processor cores interconnected by a fast digital system interface, and that means the Artida can obtain clear echocardiographs and a high diagnostic accuracy, Toshiba pointed out. 'A MultiCast beamformer uses advanced digital signal processing to control the shape of the ultrasound beam more precisely and flexibly than in comparable systems. **SmartFocus is the first 4-D** technology applied to conventional 2-D imaging transducers that offers a finer and more uniform ultrasonic beam in all three dimensions, resulting in an improved image quality from the very near to the very far field.'

The new Tissue Enhancement Mode, which suppresses white noise effectively, enhances image uniformity and endocardial border delineation could be strengthened, the company added, particularly in difficult-to-scan patients.



'The panoramic angle of up to 198° at endocavity diagnosis enables excellent orientation. User-specific optimization of image resolution is possible via the frequency spectrum of 2 - 15 MHz and the 5-tier frequency mode.

Digital platform


Due to the fully digital and 'open' system architecture and high performance the equipment is prepared for future developments. It can be integrated in a LAN as well as a DICOM high-performance

HYGIENE SPORES SIMPLY WIPED OUT

Gama Healthcare has developed an advanced innovative wipe — *Clinell Sporicidal* — which, the company reports, is the world's first peracetic acid generating wipe specifically designed to deal with spores. The wipe was developed by a team of medical doctors and contains patent pending technology designed around the stability of the peracetic acid, the company adds.

'Clinell Sporicidal offers an easier and much safer option than the chemicals currently recommended to deal with spores such as Chlorine and Glutaraldehyde based compounds. The wipe is activated with the simple addition of water, which produces peracetic acid instantaneously to levels which are proven to kill all known germs. Peracetic acid works extremely well in dirty conditions (unlike Chlorine) and can be used directly on fresh blood spills, which will activate the wipe immediately without the need for water. The fumes produced are non-toxic, which allows for use in close proximity to patients. The breakdown products are environmentally friendly and contain no alcohol or organic solvents.

'Clinell Sporicidal is the most powerful wipe to ever be created and its development constitutes a major advancement in wipe technology and infection control. In addition, it is set to become the gold standard for dealing with spore outbreaks in hospitals and healthcare institutions across the world.'



Light in weight, compact design makes system truly mobile - anywhere, anytime Universal premium


7

network. Clinical images are transferred to a PC as JPG or bitmap data, and also can be stored on a USB stick for transfer to a PC outside of the network or to give to a patient.

The newly designed keypad makes neighbouring keys easily accessible via the central trackball, Shimadzu reports. 'The most frequently used functionalities are arranged within easy reach. Diagnosis specific presettings enable fast and targeted operation of the system. Freely programmable function keys support individual physician requirements and optimize workflow.' *Further details: www.shimadzu.de*







Paediatric interventional ultrasound ('Safety first')

By **Professor György Harmat MD** (right), Director General of the Budapest Municipal Council Pal Heim Children's Hospital, Hungary

With the rapid development of new instrumentation it is now possible to carry out interventional procedures on ever younger children and even neonates.

Ultrasound guided therapeutic interventional procedures may also be carried out in certain clinical circumstances where the alternative would be operative intervention e.g. the drainage of intra-abdominal abscesses or accumulated peritoneal fluid. In many cases this will result in a definitive cure.

The most frequent inter-

vention is the parenchymal biopsy.

In childhood the pain sensitivity is always individual. Sudden artificial movements are possible. We perform biopsies in the operating theatre, with US guidance attachment.

During our 17-year experience, we have undertaken 366 procedures on 125 children.

Biopsy samples should be taken from children between two breaths with suspended ventilation. The anaesthetist is able to manually ventilate the child allowing the procedure to be performed in the 20 to 45 sec-

ond pause between ventilations. Using this technique we have not observed any damage to the solid abdominal organs.

During sampling with a special True-cut needle of 18G, the accurate place and dimension of the invasion can be chosen. Control examinations have been performed after 1, 12 and 24 hours of the first intervention. Other interventional procedures, such as drainage, peritoneal lavage, pleuritis punction, abscess or pseudocyst drainage or antibiotic treatments are also performed under general anaesthesia.

In our series, the clinical indi-




ITAL TBS is a Europe's leading group in the management of integrated services of Clinical Engineering & Endoscopy, Medical IT and Teleassistance & Telemedicine. Employing over 1.000 personnel and operating in 9 European countries the ITAL TBS Group is the largest Multivendor Services provider in Europe.

TRAUMA CARE Using high energy ultrasound to control internal bleeding

In the ongoing quest for technologies that result in as little damage as possible when used in surgery, therapeutic ultrasound stands out because it can offer what no other technology does: non-invasive, bloodless ablative surgery. Whether it is an emergency operation to staunch deep internal bleeding, or an elective procedure to remove a tumour, ultrasound has been shown to provide an effective method that can deliver ablative energy to deep-seated tissues, while requiring no incision in the skin or surgical exposure of the tissues of interest.

This technology, dubbed High Intensity Focused Ultrasound (HIFU), relies on the ability to focus ultrasound waves on a region about as small as a grain of rice, positioned at any desired depth in soft tissues. The main difference between HIFU and diagnostic ultrasound imaging is in the levels of applied acoustic intensity,



cations for interventional procedures have been for biopsy intrahepatic cholestasis with portal fibrosis, hepatic tumours such as hepato-blastoma, some at a very early age, chronic persistent hepatitis, Niemann-Pick storage disease, giant cell hepatitis, nephrosis, nephritis, ovarian tumours, neuroblastoma and different other tumours, as well as varying intraabdominal abscesses requiring drainage, peritonitis, pancreatic pseudocyst.

Taking 'safety first' as our most important consideration, we have found a very low frequency of minor complications in our cases. We have detected some capsular, subcapsular or perirenal haemorrhages, however these disappeared within 24 hours and could not be observed at follow up. Once, after biopsy, a temporal blood clot was detected within the gall bladder. We have had no major complications.

Conclusions

In children, general anaesthesia should usually be used to avoid

ITAL TBS IS LOOKING FOR POTENTIAL DISTRIBUTORS AND AGENTS for its endoscopy maintenance services to be provided to healthcare institutions in the following countries: Finland, Denmark, Sweden, Norway, Ireland and Turkey.

If your company has an interest in selling our services, please visit us at our booth **no. E34, Hall 6 in Medica** (Dusseldorf) from 14th to 17th November'07 for closer enquiry or contact us ahead of time to set up a meeting at sales@italtbs.com.



ITAL TBS S.p.A.

AREA Science Park - Padriciano, 99 - 34012 Trieste, Italy Tel. +39 040 92291 - Fax +39 040 9229999 - www.italtbs.com - email: info@italtbs.com involuntary movements.

An early diagnosis of serious illnesses is possible by this very successful combination of ultrasound and biopsy. It does not cause any complications, and due to general anaesthesia during the procedure, children have not suffered. By applying instrumental breathing, damage of the parenchymal tissues can be avoided.

It should be emphasised again that ultrasound guided interventional procedures in children should always be performed with great care. The use of general anaesthesia minimises complications and this is a significant difference in practice between adults and children.



By **Shahram Vaezy**, Associate Professor of Bio-engineering at the University of Washington, Seattle, and **Vesna Zderic**, Research Associate at the Centre for Industrial and Medical Ultrasound, Applied Physics Laboratory, George Washington University, Seattle

while both use similar frequencies in the range of 1-10 MHz. In ultrasound imaging, low intensity waves of about 0.1 W/cm2 are used to reflect from tissue structures to be resolved in the image, and in HIFU, high intensity waves of about 1000 W/cm2 are used to cause instant coagulative necrosis and tissue disruption.

The application of HIFU to the haemorrhage control problem (often called acoustic haemostasis) stems from the need to have an effective method to stop bleeding in 'the golden hour' after severe traumatic injury, involving profuse bleeding. Many trauma patients suffering injuries with high bleeding rates expire during transportation to hospital, or on the operating table, due to haemorrhagic shock (particularly true for battlefield victims).

In general, cessation of haemorrhage using extrinsic, interventional methods is possible with delivery of energy to bleeding tissues, i.e. cauterisation. We have shown in preclinical studies in large animals that bleeding from injuries of liver, spleen, kidneys, and major blood vessels (femoral and carotid arteries, jugular vein, aorta, etc) can be stopped using HIFU within a minute or so. The mechanisms of acoustic haemostasis include thermal and potentially mechanical effects. Temperatures above 70 degrees Celsius can be produced in the targeted tissue within seconds. Further, it appears that boiling of interstitial fluids and blood, as well as acoustic cavitation (i.e. formation of microbubbles at the focus due to mechanical HIFU effects) are also involved in acoustic haemostasis. The biological effects are believed to include coagulative necrosis due to high temperatures, and mechanical disruption of tissue structures potentially leading to release of tissue factors enhancing the coagulation, coagulum and thrombus formation at a wound site, tissue fusion via collagen and elastin remodelling, and fibrin plug formation.

HIFU integrated with ultrasound imaging offers a unique potential for developing a small portable device that can be brought to the site of an accident. Such a device can be used to detect and localise the bleeding site using ultrasound imaging and t stop the bleeding using HIFU, all in real-time, using a seamless imageguided therapy system. Currently, the ultrasound imaging systems can be as small as a laptop and the HIFU devices can fit in a small suitcase. Further development of these devices would provide automation of the bleeding detection and treatment methods to facilitate its usage by paramedics and other first responders. A haemorrhage control device for use outside hospital settings shortly after injury occurs, and capable of site-specific treatment, could provide a life- and limb-saving tool in trauma management.



The radio-surgical device radioSURG 2200 has been developed to provide the surgeon with a unit suitable for any surgical procedure, the manufacturer Meyer-Haake reports. Due to a new, innovative technique, minimal heat is produced, and an incision can be made without any pressure or tension. As a result, enormous precision is achieved and the surrounding area experiences no thermal damage, the company points out.

A further asset: tissue samples can be histologically examined. Surgeons can examine this device at MEDICA — Hall 5. P21 Details: www.meyer-haake.com



Please visit us at MEDICA -Hall 10/Booth number A56

9

The breakthrough effect

At GE Healthcare, we believe an innovative idea can achieve transformational results. We focus on Ultrasound applications that will create new clinical value for you and your patients. Then, we bring them to life through annual breakthroughs within our **LOGIQ**[¢], **Vivid**[¢] and **Voluson**[¢] product families.

It s all about giving you the freedom to see Ultrasound in brand new ways. Volume ultrasound. Compact ultrasound. Powerful IT solutions. All the latest technologies from GE - designed just for you. Imagine the effect. **Ultrasound Re-imagined**

Contacts: adasi@u.washington.edu vesna@u.washington.edu

Careful removal of a nevus to obtain beard growth

For more information about GE s ultrasound products, please visit us online at gehealthcare.com.



¹ 2007 General Electric Company GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC, a subsidiary of General Electric Company, doing business as GE Healthcare. GE Ultraschall Deutschland GmbH Beethovenstr. 239, D-42655 Solingen T: 49-212-28 02-0, F: 49-212-28 02-28





Premium GE ultrasound technology at 'economy class' cost

Today, ultrasound is present in most specialised medical fields, and even used in small practices. However, in terms of quality, when using ultrasonic equipment in the low price segment, users often had to compromise in terms of quality. This has been not only to do with resolution, but also the granulation typical in an ultrasound image.

This year at MEDICA, GE Healthcare is introducing its new 'economy class' ultrasound device that, GE reports, integrates high-performance with high-end technology. 'The LOGIQ A5 Primare permits only monochrome B-images - but these are of a very high quality, because the hard- and software are taken from the considerably more expensive medium-class system LOGIQ P5. The two-dimensional B-mode provides an optimised view of the anatomical conditions as well as, if necessary, of pathological changes in organs and tissues. The possibility of Doppler ultrasound to record the blood flow speed in vessels has foregone in the member of the LOGIQ family.'

Thanks to its refined multiple focusing, the system delivers a local resolution that corresponds with that of the high-end class and can also be optionally equipped, in the 'Premium' version, with GE's unique speckle reduction, the company adds. 'In this connection, the graininess typical of the ultrasonic image is recognised as an artificial phenomenon and eliminated. The result is an amazingly realistic representation of the tissue and its fine structures, which comes close to that of the MRT. New image processing techniques such as Phase Inversion Harmonics or CrossXBeam provide a clear definition of boundary surfaces, reduce artefacts as well as the background noise, in order to distinguish more clearly between cystic and echo poor lesions more clearly.'

In addition to routine applications in general and internal medicine, the LOGIQ A5 Primare is suitable for more specialised investigations e.g. in orthopaedics, rheumatology or paediatrics, GE points out.

The ProSound α 7

With over 200,000 ultrasound systems delivered worldwide, ALOKA, which has been a leading innovator in ultrasound for half a century, continues to enhance the ProSound family of high performance products. At MEDICA this year, the company is introducing its latest development: the ProSound α 7. To deliver high definition images on a LCD monitor, ease of use and a compact form design, the ProSound α 7 combines innovative technologies with renowned reliability and high industry standards of the ProSound platforms.

Visit Aloka at Medica Hall 9 Booth A74

The new system was developed to meet the needs of modern imaging departments for daily patient care where examination time and workflow must be continuously optimised. To deliver higher patient throughput, the ProSound α 7 offers a user friendly design for multiple users. It consists of user-customisable panel switches, a virtual keyboard to make entries via the touch panel, the integration of a gain knob and freeze switch, which can easily freeze images, and fast access to all frequently-used keys, arranged around a trackball. The reporting functions for individual applications



Aloka's powerful yet compact and friendly ultrasound system for daily patient care

reduce the time required for a series of examinations. A comprehensive data management system with high-level DICOM network compatibility provides efficient imaging and data administration.

With important breakthrough flow display technology, the system offers Directional eFLOW, D-eFLOW, a new innovative blood flow capture and display mode offering increased accuracy in blood flow detection of low velocity flow as well as acute acceleration non-invasively. Aloka has also developed a technique that not only helps early detection of atherosclerosis but also helps to identify patients who are prone to the indication even before the usual clinical symptoms appear. Echo tracking, eTRACKING, is a proven technique that picks RF echo signals from blood vessels, tracks the motion of the vessel walls, and measures changes in blood

New OR Device Integration Products from NDSSI



CONNECT OR



Applications Supports Cart-Based or OR-Based Imaging Stream Quality Surgical Video on Any Bandwidth, IT Network Real-Time Video Switching Control

HD 🍈

125

ndssi.com

Enable and Control Simultaneous Viewing of Multiple OR Imaging Sources
 Route High Resolution Images To Any USB Compatible Printer
 Convert any Surgical video to Fiber Optic Transmission
 Record Videos and Stills of Surgical Procedures on a PC or USB
 Stream Surgical Video to Multiple Clients
 Unlimited Viewing Software Included
 Affordable Class-I Medical Device



Microbubbles and ultrasound to treat ischemic stroke

A new research collaboration to study the potential of microbubbles and ultrasound to treat ischemic strokes has been established between ImaRx Therapeutics, a biopharmaceutal company in Tucson, Arizona, and the Philips' Medical Systems division in Andover, Massachusetts.

Philips ultrasound technology is to be used within the ImaRx's SonoLysis programme* to develop new treatment for acute ischemic stroke. Under the agreement, Philips will provide ultrasound devices and technical assistance to ImaRx during its laboratory and preclinical studies using the ImaRx's proprietary MRX-801 microbubble technology to determine the optimal ultrasound parameters to be used.

The vast majority of strokes, According to the American Stroke Association, about 87% of strokes are ischemic, i.e. caused by blood clots that block normal blood flow in brain vessels. Additionally, Datamonitor reports that less than 6% of the ischemic stroke patients receive the thrombolytic drug tPA, the only drug currently approved by the FDA to treat acute ischemic stroke.

'This research collaboration represents a significant step forward for ImaRx's SonoLysis programme,' added Bradford A Zakes, President and CEO of ImaRx Therapeutics. 'By working closely with Philips Medical Systems, we are incorporating the leading ultrasound technology and expertise into the early stages of product development, which strengthens our position as we move further through our clinical trials.'

Anne LeGrand, senior vice president and general manager of Ultrasound, for Philips Medical Systems, confirmed that Philips recognises the promise of microbubble therapies.

vessel diameter. Important parameters such as Pulse Wave Velocity, Augmentation Index, and Stiffness are measured in one step, non-invasively, with an extremely high degree of accuracy.

ProSound a7 offers sophisticated cardiovascular examination functions such as the KI/A-SMA function that automatically traces the endocardium for quantitative assessment of wall motion based on the area change of the cardiac cavity segments or a TDI analysis, which let the region of interest follow the same point on the myocardium at any time phase of the cardiac cycle; this enhances the accuracy of wall motion velocity analysis. Accuracy is also ensured for the asynchrony measurement, because of the high frame rate which leads to an optimal time phase analysis in the M-mode, the D-mode and TDI.

The companies' agreement includes a mutual exclusivity clause during the term of the collaboration. Following completion of the research programme, Philips and ImaRx will have an exclusive negotiation period to discuss future development and commercialisation.

The ImaRx' SonoLysis research programme

The company focuses on developing and commercialising therapies for stroke and other vascular disorders. (Current commercialisation efforts are focused on its product, Abbokinase as a treatment for acute massive pulmonary embolism).

The aim of this research programme is to develop product candidates that involve the use of the firm's proprietary MRX-801 microbubbles with ultrasound to break up blood clots and restore



blood flow to oxygen deprived tissues. The sub-micron size of MRX-801 microbubbles may allow them to penetrate a blood clot, so that when ultrasound is applied their expansion and contraction, or cavitation, can break the clot into very small particles, ImaRx reports. 'ImaRx is conducting an ongoing Phase I/II multinational clinical trial evaluating its SonoLysis+tPA therapy to treat patients with acute ischemic stroke.'



Smart Ultrasound for better patient care

THE POWER TO DELIVER BETTER PATIENT CARE

Leading practitioners around the world are turning to the power, portability and precision of Ultrasonix to deliver better patient care in their daily practice. From OB/Gyn to Emergency Medicine and General Surgery, practitioners are enjoying greater diagnostic confidence, adding to enhanced procedure planning, and faster decision making. Sleek, maneuverable and intuitive, Ultrasonix provides the ultimate balance of features you need to deliver better patient care.



Areas of use:

The ProSound α7 offers ultrasound imaging applications in radiology, internal medicine, obstetrics & gynaecology, cardiovascular and other specialist ultrasound-guided procedures. *Full details: www.aloka-europe.com*

For more information, please visit us at booth #10D65



Study finds cartilage implant promising

Poland – At September's International Cartilage Repair Society Annual Meeting (ICRS), in Warsaw, participants heard that a neocartilage implant called Neo-Cart, made by US firm Histogenics, is safe as well as promising.

NeoCart is an autogenous neocartilage implant grown by seeding a patient's own cartilage cells on a collagen matrix. A patented, high-pressure tissue engineering

processor is said to produce more natural neocartilage than other techniques.

Dennis Crawford MD PhD, Assistant Professor of orthopaedics and surgical director for Sports Medicine & Cartilage Reconstruction at Oregon Health & Science University (OHSU), was reporting on an FDA Phase I safety trial that involved seven patients treated with NeoCart at OHSU, with a 2-year follow-up. All

patients showed good cartilage

fill and integration with surrounding cartilage. Knee joint function was improved in six of the seven patients. Advanced MRI techniques showed that the NeoCart treatment had resulted in the formation of true hyaline cartilage in four of the seven patients, Dr Crawford pointed out. 'This novel therapy may replace microfracture to become the next primary treatment for cartilage injury to the knee. Patients are getting pain relief for at least two years, the technology can be applied via a simple out-patient procedure and it appears by our best radiographic methods to mature and stabilise over time,' he added.

Device helps heal the meniscus

Faced with meniscus injuries surgeons usually decide to remove the torn meniscal cartilage, which typically leaves the deficient knee vulnerable to future arthritis, because the padding that provides shock absorption and joint stability has been removed, causing bone to rub on bone.

A new knee-surgery device to help repair 'irreparable' meniscus tears has been approved by the FDA for use in humans. The BioDuct Meniscal Fixation Device was developed by Herb Schwartz, president and CEO of Schwartz Biomedical, LLC, and James Cook, MU professor of veterinary medicine and surgery and William C. Allen, Endowed Scholar for Orthopaedic Research in University of Missouri-Columbias' College of Veterinary Medicine, which they believe can save the

Point-of-care

from SonoSite

Hall 9 Booth E31

ultrasound

meniscus as well as long-term knee function.

The device transports blood and cells from the vascularised knee area to the avascular area of the meniscus, to enable healing.

The research team performed the BioDuct surgery on 25 canines - complete or partial repair of the meniscus was observed in all cases that received the BioDuct Meniscal Fixation Device.


Herb Shwartz pointed out that this new device could have a considerable impact on orthopaedics because with fewer meniscal tear patients developing arthritis there could be fewer total joint replacements, or a delay in the need for one.

The study results have been published in the American Journal of Sports Medicine.



Seeking enterprising distributors

A progressive international medical instrument manufacturer of tourniquet systems from North America is seeking qualified distributors to represent its products in the European and Middle East market. For live presentation of available models and further discussion, please contact by e-mail at dsales02@gmail.com or call +1 (604) 688 1680.



At Medica, this year, SonoSite is presenting innovations - M-Turbo and the *S*-series – which present numerous technical improvements and deliver a breakthrough image quality, the company reports. 'With the S-Series, SonoSite launches a radically new concept in ultrasound unlike anything else in the market.

· 888888

Highlight is the S-Nerve visualisation tool, the first ultrasound device custom-designed to support the specific needs of anaesthesiologists who perform regional anaesthesia,' the manufacturer explains. 'The new SonoSite products can perform a variety of examinations and deliver high quality diagnosis even under difficult condi-

tions. Thanks to a large capacity for image and data transfer, the mobile ultrasound systems provide many possibilities for lower cost, multi-media hospital communication. Therefore, it's not just patients who benefit; hospitals are also experiencing benefits due to decreases in costs.'

PD-Q: A screening tool to identify PAIN neuropathic components in pain patients

Every fifth Dr Rainer

European is suffering chronic pain, according to the recent 'Pain in Europe Survey'. However, there

Freynhagen are pains and other kinds of pain, as particularly seen in patients with neuropathic pain.

At the German Congress for orthopaedics and Trauma Surgery new diagnostic and treatment methods were described that might promote better pain therapy. Usually doctors classify pain according to an accepted system that is based on the type and extent of the prevailing dysfunctions. 'However, it is not the dysfunctions but the underlying pathophysiological mechanisms the pain is based on which are decisive,' said neurologist and psychologist Professor Thomas R Tölle MD, who is Head of the Pain Surgery at the Neurological Clinic in Munich's Technical University. Pain, he said, can be traced to

nociceptive and neuropathic mechanisms. 'Neuropathic pain development, caused by lesions or dysfunctions of peripheral nerves or central nerve tracts, takes a severe course: Based on inflammatory processes, the patients develop physiological changes that lead to hyper-sensitised, peripheral, spinal and supraspinal signal processing. Patients with neuropathic pain require specialist and

need to detect the symptoms but the nerve damage.'

'Up to now we have not had any method to diagnose neuropathic pain at an early stage on a large scale,' added pain therapist Rainer Freynhagen MD. With a research associate and team at the Anaesthesiology Clinic at Düsseldorf University Hospital, 47,000 patients have been examined in a project called nainDETECT. 'We discovered that patients with neuropathic pain complain about long and severe periods of pain with relevant loss in functional efficiency. Moreover, characteristically they tend to suffer from particularly pronounced comorbidities, such as sleep disorders, panic attacks and anxiety or depression.' Based on the collected data the researchers developed a painDETECT questionnaire (PD-Q) – a list of questions that can be completed by patients and their doctors within a few minutes. 'The painDETECT questionnaire in no way replaces regular

Emergo Group is an ISO registered consulting firm. Since 1997. Hall 16/C05

Let us help you! Regulatory approvals. Distributor search.

- > European Authorized Representative > US FDA 510(k) & FDA GMP consulting
- > CE Marking & ISO 13485 implementation
- > Distributor search & management plus market entry strategy

Full regulatory, quality, and distribution management services for China, Japan, Australia and Canada too!



intensive treatment.'

At the DRK Pain Centre in Mainz, neuropathic pain is currently being documented from comprehensive physical examinations, laboratory tests, electrodiagnostics, imaging, biopsies and quantitative sensory testing (QST). Professor Hans-Raimund Casser MD, the Centre's medical director, said: 'We have to intervene in these inflammatory processes as early as possible to prevent nociceptor sprouting and chronification of the pain. But even achieving a precise diagnosis is difficult and complex, because we don't



DERMATOLOGY



Children with recessive dystrophic epidermolysis bulosa (RDEB) lack a protein that binds the skin to the body,

resulting in fragile

skin that sloughs off

Wagner

with little movement or friction. In the most severe cases, the skin also sloughs off inside the body, affecting the mouth, oesophagus and gastrointestinal tract. EB is genetic and severe forms are fatal. Those who live to be young adults develop squamous cell carcinoma.

Now the first bone marrow and cord blood transplant to treat RDEB has been carried out by physicians at the University of Minnesota Children's Hospital, Fairview, with the collaboration of researchers at Columbia University, University of Minnesota, on an 18-month-old boy suffering the most severe form of RDEB.

With the help of an EB mouse model the researchers corrected the disease in mice using bone marrow. They tested various types of adult stem cells to determine which would promote the development of type VII collagen — a protein that patients with RDEB lack. One type of immature cells from bone marrow proved the best at producing binding fibrils that hold skin and body together.

This is the first approach to EB from a systemic perspective, using transplant as a method to rid the body of the defective blood system and replace it with a healthy blood system that produces type VII collagen.

The child received both umbilical cord blood and bone marrow from a perfectly matched sibling. If the results mimic the animal model, doctors anticipate the healthy blood system will aid in the skin's ability to produce type VII collagen necessary to anchor the skin and lining cells of the gastrointestinal tract to the body. Doctors anticipate in early 2008 — approximately 100 days after

diagnostic procedures, but it is an important aid because the calculated score has a high significance as to the prevalence of neuropathic pain components,' explained Dr Freynhagen, who this year was awarded the 1st promotional prize for pain research.

The questionnaire, which is now available in fourteen languages, paves the way for early, individually adapted medication. Good treatment results are currently being achieved with Pregabalin (LYRICA, Pfizer). Licensed since September 2006 for the treatment of central neuropathic pain, Pregabalin modulates a calcium influx into the nerve cell and leads to a reduced release of excitatory transmitters. It not only weakens the course of the pain and its intensity but also eases mental and somatic symptoms, such as sleep disorders and anxiety. 'I admit that we do not yet know all of the pathomechanisms. But we are getting very close with our methods and have achieved significant therapeutic success,' Prof. Tölle concluded.

Infant receives first systemic therapy to treat RDEB

transplant – they will be able to judge whether this treatment helped.

The paediatric BMT programme at the University of Minnesota Children's Hospital, Fairview, is internationally recognised for pioneering umbilical cord blood and bone marrow transplantation, including the world's first successful BMT in 1968. In 2000, a team led by John E Wagner MD, professor of Paediatrics and director of the Division of Haematology, Oncology, and Blood and Marrow Transplantation and director of clinical research of the Stem Cell Institute, University of Minnesota, performed the first umbilical cord blood transplant from a sibling donor 'created' after embryo selection. The programme leads the nation in the use of umbilical cord blood in the treatment of adults and children and in the development of innovative treatments of various rare genetic diseases such as adrenoleukodystrophy (ALD) and Fanconi anaemia.

Of this recent transplant, Profes-

sor Wagner said: 'Our goal is to determine the usefulness of stem cells, whether from the umbilical cord blood or adult tissues like bone marrow, in the treatment of human disease. Hundreds of thousands of children and adults are waiting for new breakthroughs in stem cell research, and time is never enough. In two years, the team was able to move this project forward remarkably fast from testing in animal models to treating patients. Time will tell whether this risky treatment will work as effectively in humans. But, RDEB is a horribly debilitating, lifethreatening disease with no existing curative therapy.'

THERAPIES

Maria Hordinsky MD, head of the Department of Dermatology at the University of Minnesota and a member of the care team, added: 'This represents a real change in thinking within the dermatological community. The possibility of this approach compels us to explore more broadly the way some skin diseases are typically treated.' *Source: Molly Portz, University of Minnesota*





2007@MEDICA





MEIKO Maschinenbau GmbH & Co. KG · Englerstraße 3 · 77652 Offenburg · Germany Telefon +49 781/203-0 · Telefax + 49 781/203-1229 · www.melko.de · E-Mail: info@melko.de



HEALTHCARE MANAGEMENT



lid: +44 (0) 845 2011 644 enal: sales@ganabealficares www.ganabedit.com.com

he increased need of medical care among ageing populations is causing cost explosions across Europe. Some countries tackle this challenge with Managed Care processes: Controlled interventions in the healthcare system aimed at getting doctors, patients and insurers to follow a more balanced, forward-looking path. Using different control models, the Netherlands and Switzerland have shown that it is possible to achieve significant cost savings without any loss of the quality of care.

Competition, bonuses and competent patients secure the future

'Fewer and fewer workers must care for increasing numbers of patients. Our system is on the brink of collapse - something has to hap-

save money,' Prof. Caris explained. Therefore, the Netherlands additionally implemented a reimbursement system whereby patients who only had basic medical care from their GPs were reimbursed contributions of up to 255 Euros. Patients can also make additional savings if they join group contracts or agree to take on part of any treatment costs, if and when they arise: 'These simple measures have proved to be very effective. People now get more involved in saving money and develop more realistic expectations' the professor pointed out. 'Too much control and regimentation, on the other hand, is bad for the healthcare system.' According to this expert, action is also needed from the doctors: Efficient treatment is based on three

Prof. Caris cites as a positive example the treatment of children with attention deficit hyperactivity disorder (ADHD). Here the combination of medication, supportive family therapy and the strengthening of their own competence for those affected, by, for example, making their daily routines more structured, is having the maximum effect. 'Better quality at lower costs: To achieve this goal, patients and healthcare professionals should be ready for the market,' Prof. Caris concluded.

Control of medical treatment and quality assurance is down to the GP

The introduction by law of Managed Care in Switzerland occurred as far back as 1996. Other than in The Netherlands, the system is not

Top down or bottom up? Managed Care in the Netherlands and Switzerland

pen,' said Professor Jo Caris of the TIAS Business School in Tilburg, the Netherlands, during the BMC 'Managed Care Congress inEurope'.

In January 2006, the Netherlands introduced a new medical insurance law in January 2006 that moved the system away from the principle of comprehensive solidarity and closer to a system based on competition, self-regulation and choice: Every adult Dutch citizen takes out a basic insurance services package, regulated by the state, with a private medical insurer, which is independent of income and currently set at 1,050 Euros a year. In addition, contributions of 6.5%, which are dependent on income, have to be made, most of which are covered by employers and form the basis of the risk structure compensation scheme. 'Changing the financing system in itself does not prevent the uncontrollable consumption of medical services though. We had to emphasise to patients that medical care costs money and give them incentives to



Peter Berchtold MD Professor Jo Caris things: Specific medical therapy, referral to supportive social institutions and enhancing patients' health competence. 'We tend to start largescale campaigns that point out to people that their lifestyles are damaging and which actively encourage them to stop smoking. But, when people are actually ill, we only involve them in their own treatment in a more passive manner. The patient is therefore put under tutelage. He feels left alone, is scared and lacks the competence to help himself when he is ill. We have to give patients more and better information about their illnesses and increase their ability to act. Competent patients can make significant contributions towards avoiding unnecessary costs.'

MEDICAL TOURISM Ophthalmology

UK-based company StatMedica specialises in medical tourism in Poland and has been appointed to represent several leading Polish eye surgeons who operate in high-tech clinics in major cities across that country, reports Alison Hope, the firm's Managing Partner in London. Clinics represented by the firm offer a wide range of elective procedures, including refractive surgery, cataract removal and corneal transplants. The StatMedica team assists with communications between patient and clinic and arranges an in-depth consultation with the opthalmologist prior to a patient's departure from the UK to Poland, Alison Hope adds. Warsaw-based managing partner, Lukasz Lies, leads the Polish team, which provides a range of services, from airport transfers to 24-hour care by a qualified professional.

* Source, StatMedica Research



regulated top-down, but bottom-up, with the legislator almost completely passing on the responsibility for efficient and cost-effective medical care for the population to general practitioners (GPs). This system is based on so-called medical networks around 56% of doctors have so far decided on interdisciplinary co-operation within an integrative network. 'Within the medical network, the GP as the gatekeeper is the central point of contact for patients. In case of illness, people are always initially seen by their GPs. The GP controls medical services and, if required, refers patients to specialists within his network. Through the co-ordinated control by one person therapy turns out efficient and cost-effective and duplicate examinations can be avoided,' said Dr Peter Berchtold, of Forum Managed Care, Switzerland. 'Compared with traditional care, the cost saving lies at between 10% and 35%,' he continued. 'Doctors who have become part of these networks show a lot of their own initiative. They are not only interested in cutting costs but also in quality assurance. There have been particular improvements in information transfer. A computer network that documents all therapeutic measures in electronic form and is accessible for everyone involved in treatment, was also set up alongside the medical networks over the last few years. Patient safety has increased significantly.'

More quality and more safety - the new system also appeals to patients, particularly as it is worthwhile financially. About 30% of all those with medical insurance decided on treatment within a particularly medical network and therefore received bonuses of up to 20%. Regular contributions can also be lowered if patients agree to take on a higher share of costs, if and when they arise. 'The system of differentiated, additional contributions is very popular in Switzerland, he said. 'Many patients also use the telephone advice services that have recently been introduced. These provide competent information before costs even arise. So far the managed care measures implemented have been mainly restricted to out-patient care and less so to inpatient services. Hospitals, rehabilitation clinics and outpatient care services should follow suit. Dr Berchtold believes. 'Co-operation and networks are becoming increasingly important as health is always an interdisciplinary matter. Those who don't co-operate will not survive within the healthcare market of the future'



NEWS

MRI and magnetic fields EU Directive postponed for amendment

based and founded on sound sci-

ence. There has been no proven

harmful effect of MRI to either

patients or workers over the past

25 years, during which time over

500 million examinations have

been undertaken.' The Alliance for

MRI believes that it is essential to

evaluate the real risk to patients

which would be brought about by

impeding the full use of MRI,

The European Commission (EC) has postponed the EU Directive that would have affected the use of MRI until 30 April 2012, to allow time for a substantive amendment to be adopted. The Alliance for MRI said it welcomes the Commission's statement that '... the future amendment will aim to ensure that limits will not have an adverse effect on the practice of MRI' and the recommendation to Member States to put the transposition of the current Directive on hold.

'MRI is a powerful, non-invasive and safe diagnostic and research tool,' said Professor Gabriel Krestin, Professor of Radiology at Erasmus MC, University Medical Centre Rotterdam, in the Netherlands, and a leading member of the Alliance for MRI. 'However, its application often relies crucially on the presence of a healthcare worker or researcher. If the EC legislation were implemented, it would almost certainly impact on patient welfare and be a major setback for research. scientific denving patients innovative treatments in the future.'

In June 2007, the Alliance for MRI held a lunch at the European Parliament with Commissioner Spidla to discuss research undertaken by Professor Stuart Crozier of Brisbane University, Australia* that vindicated the Alliance's concerns.

In addition to its serious impact on healthcare, the Alliance believes the Directive would threaten Europe's position as world leader in MRI research, as recognised in the Nobel Prize awarded to Sir Peter Mansfield. MRI is a leading example of where the EU stands in cutting edge research.

'We look forward to working with the European Commission prior to the proposal to amend the directive,' Professor Krestin said. 'It is essential that the European Commission assesses closely the full impact the directive will have, taking into consideration the social, economic and environmental impact of the legislation. Any new legislation must be evidence-

Magnetic Resonance Imaging (MRI) scans produce detailed pictures of the inner structure and function of patients' bodies using magnetic fields and radio waves. Its use has become an essential tool in diagnosing and treating illnesses such as cancer, cardiac diseases and neurological problems, and in medical research for the same disorders.

The EU Physical Agents Directive 2004/ 40/EC (EMF), however, would prevent medical staff from assisting or caring for patients during MRI imaging, due to concern over the effects of the magnetic fields generated. against the notional and unproven risk to workers.

The safety of MRI workers is already regulated by the EU Medical Devices Directive (amend. Direct 93/42/EEC) and the established MR safety standard IEC/EN 60601-2-33 (as amended to include users/workers). The IEC standard establishes limit values for timevarying electromagnetic fields which have been set, so that any danger to patients and workers is excluded.

* Study Commissioned by the UK Health and Safety Executive http://www.hse.gov.uk/research/rrpdf/ rr570.pdf



The DCA Vantage Analyser from Siemens Medical Solutions Diagnostics is a user-friendly, point-of-care (POC) patient management platform for diabetes. It provides glycosylated haemoglobin (HbA1c), microalbumin/creatinine and albumin-to-creatinine tests. Physicians can enter a patient ID, via the touch screen or barcode, view on-board printed reports and graphs of HbA1c trends.

The system is network-ready. Test results can be shared within the office, clinic, among coordinated POC or can be easily uploaded to an external healthcare information technology (HIT) system.

Besides glycaemic control the microalbumin/creatinine measuring capability of DCA Vantage helps physicians by early detection of kidney disease, a common complication of diabetes. The onboard glomerular filtration rate (GFR) calculator assists in kidney disease staging.



The Alliance for MRI, which represents a coalition of European Parliamentarians, patient groups, leading European scientists and the medical community, has campaigned to bring attention to the potential loss to patients.

'The increase in cancer survival seen over the past decades is, to a large extent, due to more precise diagnostic tools - MRI included,' said **Professor Dag Rune Olsen, Chairman of ESTRO Physics Committee.** 'Impeding the medical use of MRI would have severe impact on treatment out-come of cancer patients in Europe. The European Commission must learn from their experience with this Directive and consult widely before implementing Directives that impact negatively on research and patient care.'

Simplicity is an exceptional image and a patient at ease.

Philips Achieva 3.0T X-series MR scanner. Now optimal scan quality and patient comfort go hand in hand. The Achieva 3.0T provides a remarkably large field-of-view and enhanced imaging technology to handle your most advanced applications. And the open flare, compact design is more relaxing for your patients. Keeping everyone's needs in mind just makes sense.

www.medical.philips.com/achieva





COMPONENTS & MATERIALS






Britain's biggest trade fair for medical product design and manufacturing will be held next February in the NEC Birmingham

Exhibitors will present contract manufacturing & subcontracting, component fabrication, tubing, adhesives & adhesive products, electronic components, production/assembly, packaging equipment and materials, motors & motion control, plastics, testing equipment & services, hardware & IV components, precision metalworking, tooling and machining, for use by medical device and equipment manufacturers. **3C 2008** - the Contamination Control and Cleanroom Products exhibition, focuses on products for the protection and prevention of particle infection to personnel, products, or the environment. Sections include design and construction products and services, garments and consumables, equipment and products and general services.

Details: www.devicelink.com/expo/mdt2007/









WELCOME TO THE FAMILY.

The companies of VIASYS Healthcare are now an integral part of Cardinal Health, and our mission to make healthcare safer and more productive. Count on our continued commitment to you, your patients and the healthcare profession.

Visit Cardinal Health at Medica in Düsseldorf, Germany 14-17, November, 2007 Hall 10, Booth # A40

Learn more at cardinalhealth.com/viasys

High-tech solutions for medical technology

icro and medical technology are growing together and driving one another on to new developments. According to a survey by IVAM, the Professional Association for Microtechnology (Dortmund), medical technology is the principal target sector for European microtechnology companies, with a clear lead on the telecommunication and electronic industries. Over 43% of the companies questioned replied that they regard medical applications as the primary focus of their marketing opportunities. It is therefore no wonder the international fair COMPAMED, for international suppliers in medical manufacturing, continues to boom alongside MEDICA. Again, in 2007, this event has seen impressive growth.



'Three months before the start of the COMPAMED 2007 tradeshow, the number of exhibitor applications received was over 40% higher than in 2006, and there was an increase of 48% in terms of the surface area reserved,' said **Wilhelm Niedergöker**, General Manager of Messe Düsseldorf. There are over 455 exhibitors from 30 countries and a surface area covering over 8,400m in Halls 8a and 8b.

Among the exhibitors is NanoFocus AG (Oberhausen), which is showing its non-destructive, automatable 3-D measuring systems, designed to enable surface inspection of implants or stents, among other things. Heinz-Peter **Hippler**, the company's Sales Manager said: 'With regard to our measuring technology, which ranges from the microscale to the nanoscale, we are expecting a surge in demand from the field of biomedical engineering. Accordingly, we are expecting great things from this event.' In the Innovation Report 2007, an annual publication by the Association for Electrical, Electronic & Information Technologies (VDE, Frankfurt a.M.), medical technology remains the third most important driver of innovation. Europeans lead this field, well in advance of the USA, according to this event's organisers. 'With over 70% of the technical experts, Germany and Europe can claim to have the highest innovative capacity in medical technology; by comparison, the USA has 24%. They are followed at some distance by Japan and China. Also noteworthy is the forecast for 2015, according to which not only will the





CardinalHealth Essential to care"



COMPONENTS & MATERIALS

COMPAMED 2007

order of rank stay the same, even the percentage shares are to remain plasters could make it easy to largely unmodified.'

The study of 'Optical technologies - Commercial Importance in Germany', commissioned by the BMBF, reports that the global market for medical technology and life sciences has a volume of €18.6 billion. This amount is supposed to increase to €38.8 billion by 2015, which represents a growth rate of 7.6%. Germany's share of this amounts to almost 16%. It is worth mentioning the high percentage of graduates (13%) among the 17,400 employees of the medical engineering industry, which exports 70% of its products abroad. The trends toward intelligent and

Messe Dusseldorf, the massive trade fair centre, filled annually by MEDICA and COMPAMED



multifunctional high-tech products and toward continual internationalisation are also a characteristic of COMPAMED.

Top potential for optical inspection systems

Similar to NanoFocus AG, the Optical Solutions division of Siemens is also working in the area of quality inspection, for which it offers ultrafast optical inspection systems. These can detect, for example, fractures in stents and thereby prevent micro-wounds in arteries, which can occur when parts of damaged stents straighten up in the artery. Markus Lotz from Siemens Optical Solutions sees a bright future for measuring and image processing technology, 'The development potential of optical inspection systems can be increased fivefold, because we have not yet availed of all the opportunities presented by image processing. The measurement of surface textures - down to the nanoscale would be inconceivable without modern sensors. This topic therefore stands equally high on the priority lists of the exhibitors and the visitors to COMPAMED. The components, based on CMOS technologies (Complementary Metal-Oxide Semiconductor), for example, and therefore belonging to the microtechnology sector, are also used to measure the flow rate of gases and liquids in anaesthesia systems and infusion technology, among other things. However, Ulf Kanne, Product Manager at Sensirion AG in Stäfa in Switzerland, can envisage numerous other application areas - especially for disposable sensor solutions:

'Humidity sensors integrated in monitor the healing process of burn injuries, for instance.'

Laser-modified surface properties

The on-going miniaturisation in many branches of the medical engineering sector also demands new manufacturing techniques. At this year's event, the Hannover Laser Centre (LZH) is offering a

whole batch of micro-technical manufacturing processes for medical product engineering. Along with conventional precision methods, such as laser removal, cutting and joining, other product modifications and solutions are being presented that specifically target medical applications. For example, laser processes can be used to make selective modifications to surface properties



- especially of polymer materials. In this way, through the use of microstereolithography, materials can be provided with particular liquid properties.

'Micro-fluid systems are coming increasingly to the fore in medical technology. Systems like these require new types of expertise, above all in manufacturing technology,' said Dr Roland Stangl, Director of Micro Technologies at PARI Pharma GmbH. PARItec GmbH, which is presenting current developments in this field. The firm's microtechnologies, using the example of PARI eFlow the innovative medical continued on page 18



BERCHTOL

BERCHTOLD SUPERSUITE® – FITS PERFECTLY

For more than 85 years, BERCHTOLD has been a world-wide leader in the design and manufacture of quality surgical equipment. With our focus on the operating room, we deliver **best-in-class** products, experienced planning, project management and service with a personal touch. Our know-how facilitates your individually-tailored surgical environment. Today's state-of-the-art operating room; thinking for tomorrow: the **BERCHTOLD SUPERSUITE®**.





17

COMPONENTS & MATERIALS





Bulbtronics is the source and leading distributor of lamps and batteries for all types of medical/ scientific equipment and instrumentation. Bulbtronics stocks over 30,000 line items in four stocking locations from over 150 of the top product manufacturers. 01-631-249-2272 x 352

www.bulbtronics.com export@bulbtronics.com

continued from page 17 nebuliser, are being demonstrated. The production of PARI eFlow incorporated medicine-compatible and autoclavable adhesive bonds with various materials such as steel, piezo-ceramics and plastics and involved high-speed laser drilling in steel, for holes with a diameter of two micrometers or more. The company also provides this technique as a service.

Two important elements in fluid systems of whatever size are pumps and valves. Bartels Mikrotechnik GmbH is presenting the 'mp6', its latest micro pump generation, for the first time, at the

IVAM is an international association of companies and institutes that specialise in microtechnology, nanotechnology and advanced materials. This 13-year-old association aims to open up new markets and set standards with its 242 members from 17 countries

According to its latest survey, medical technology is top of the ranking list of the European MEMS industry's most important target markets.

26 of the association's members are exhibiting at this year's COM-PAMED.

Sensor technology

Sensirion is demonstrating the use of gas and liquid flow sensors in spe-

IVAM Joint Pavilion. Equipped with a double actuator (actuator = final controlling element in a control loop), the component doubles the back pressure range to 500 mbar, while a modified signal form ensures low-noise operation. A valve with positive opening pressure, for regulating flow when the pump is not in operation, is currently being developed to go with the pump. 'The basic principle of the piezo membrane pump has been kept simple so that it can be adapted to various requirements – the customer decides whether he needs, for example, a larger



anaesthesia, ICU, homecare ventilation, CPAP, medical diagnostics, analytics and drug delivery). For example, it is illustrating the use of its gas flow sensors in medical ventilation applications, and is discussing future sensor-based products that become possible thanks its CMOSens technology to e.g. implantable and disposable solutions.

volume range, compatibility with a particular material or greater conveyor accuracy,' explained Product Manager Severin Dahms. Bartels is presenting some specimens of the implementation of such requirements at the trade fair. The prototypes of a high-pressure, a high-volume and a regulated micropump will illustrate the numerous possibilities. Complicated components like these can be applied, for example, in laboratory technology in bio-chips ('lab-onchip' applications).

Many MEDICA exhibitors migrate to COMPAMED

Many of MEDICA's 'traditional' exhibitors are exhibiting at COMPAMED this year for the first time. Along with companies such as Alike Buerkert, Binder, Degussa, Helbling and others, these include Bernd Richter GmbH (Wipperfurth) and Nicolay GmbH (Nagold), which both offer cable systems and accessories for medical technology.

Mechatronic AG (Darmstadt), which manufactures programmable electronic medical devices, as well as the corresponding components, modules and software, have switched to COMPAMED for the first time. 'MEDICA has played a decisive role in the success of our company up to now,' explained Thomas Ullmann, Chief Executive

Aceos GmbH is exhibiting three novelties: two new 02 sensors: ACE-Xmed2 with an ultra-fast response time (< 50ms), especially applied with respiratory applications for infants, and ACE-Xmed3 with a measuring range up to 60 Vol%02 for patient monitoring; also, the ACE-DXmed1 - a plug&play sensor module to measure 02 and CO2 in spiroergometric applications

due to the valuable contacts that we establish every year at the trade fair, our turnover has increased almost fivefold in the last ten years. At the same time, almost 90% of the MEDICA visitors were outside our core target audience. As a result of switching to COMPAMED, we are anticipating a significantly sharper focus on our specialised audience from the decision making bodies for new developments in medical technology.²

Quite apart from the ever increasing number of exhibitors that are presenting innovations and products from the entire field of medical technology, the 'High-tech

Officer of Mechatronic AG. 'Not least for Medical Devices' forum provides a different information focus. Organised by IVAM, it shows the latest trends, particularly regarding micro and nanotechnology for use in medicine. New materials and substances, a traditional mainstay at COMPAMED, is again the centre of attention.

Of the 137,503 professionals who attended last year's overall event, i.e. MEDICA and COMPAMED, about 13,000 experts were interested in the technically specialist range of products offered at COMPAMED. Report by Klaus Jopp, freelance

technical writer for science and technology, Hamburg.



Tiny components

The Servometer Precision Manufacturing Group, LLC, is presenting custom electroforms, which are very precise, thin-walled, light weight precision components, that can be made as miniscule as 0.020î in diameter, with walls as thin as 0.005î, made of nickel, copper, implantable gold, silver, or a combination thereof, depending on application requirements. Servometer electroforms can be used as molds, precision tubing, precision nozzles and other lightweight, structurally rigid components in various applications, including both invasive and non-invasive applications within the medical industry.


Smart Products, Inc. is introducing

its 101 Barbed Check Valve at the IVAM joint pavilion, which fits 1/8î ID tubing and is ideal for medical applications including blood pressure cuffs, kidney dialysis, post-surgery instrumentation, or any application where space is limited. Due to a spring-loaded design, the 101 plastic valve does not require pressure to close and can also be used as a pressure relief valve. A range of precise opening pressures from 2 PSI to 20 PSI are available. Also new is the 103 NPT Check Valve which mounts by screwing into a manifold. The thread size is 1/8î, and a choice of materials and opening pressures is available. Smart Products provides over three million possible check valve combinations with a modular, mix-and-match capability.

Measurement

Lasers for oxygen detection are being exhibited by eagleyard Photonics GmbH. The company has expanded its product portfolio by 760 nm and 763 nm Distributed Feedback (DFB) lasers in butterfly package. eagleyard's new DFB lasers track down oxygen by the characteristic 'fingerprint' of the absorption spectrum. With narrow line width, the lasers can sense even residual amounts of oxygen, the firm reports. A mode-hop free emission guarantees a very precise gas analysis by means of absorption spectroscopy. The lasers are designed for applications in the medical, pharmaceutical and chemical industries

IP-based Nurse Call System with Fall Alarm and Assisting Non-Body-Contact Vitals Monitoring



simultaneously



HEART RATE

The under mattress bed sensor detects ballistocardiographic (BCG) movements caused by heart beat. The DVM unit calculates heart rate (BPM) and sends the value to the monitoring software along with the filtered raw curve data.

RESPIRATION RATE

Respiration rate is calculated from movements caused by breathing. Both the calculated value and the raw data of the respiration channel are transmitted to the monitoring computer.

ACTIVITY AND GENERAL MOVEMENTS

Overall activity and general movements are recorded. The unit calculates several different activity indexes and sends

these along with the raw movement signal curve for remote monitoring.

BED SENSOR

All measurements and recognitions from the patient/bed are sensed with patented dynamic thin-film sensor. The non-body-contact sensor is placed in the bed under the mattress, invisible for the patient.

NURSE CALL BUTTON

The DVM unit has an input for a conventional nurse call button.

Emfit Ltd

Konttisentie 8 | 40800 VAAJAKOSKI | FINLAND Tel: +358 14 332 9000 | Fax: +358 14 332 9001 info@emfit.com | www.emfit.com

Bonding technology

As a system supplier, PARItec GmbH is presenting micro technologies exemplified by the novel drug nebuliser PARI eFlow. This includes bonding technology with different materials such as steel, piezo ceramics, and plastics (e.g. polyimide) for medical use, as well as autoclavable or high-speed laser drilling for holes ex 2 µm diameter. 'Micro fluidic systems are more and more common in medical technology. Such systems require new competences particularly in manufacturing technology,' said Dr Roland Stangl, Director Microtechnologies of PARI Pharma GmbH.



Please, visit us at: HALL 16, B 53

PASSAGEWAY DISPLAY The passageway or lobby / nurses' office displays show main status information and alarm events.

Meet our team at MEDICA!

EH@MEDICA - Here we are again, at the greatest medical show on earth.

As the official show publication, *EH@MEDICA* has been produced in three separate issues by our flagship magazine *EUROPEAN HOSPITAL* (EH). Each issue is packed with technological and medical innovations as well as news of medical and healthcare advances.

- On Wednesday the issue focuses on ultrasound
- In the **Thursday** issue we present progress in hospital IT systems • **Friday's** focus is on news surgical procedures and equipment

The *European Hospita*l team is at the fair (hall 7, booth E15), all looking forward to meeting you, to hand out free issues if you missed any, and to answer your queries regarding editorials or advertising. Our reporters are also circulating around *MEDICA* to catch the most interesting highlights of the fair and report about these. Their on-the-spot reports will appear, for the first time, on our homepage **www.european-hospital.com** in a special MEDICA section. So, even if you must miss the fair, you can access daily news to keep up-to-date.

In addition, because the world-wide-web and e-mail communications have

And collect your FREE copies of our medical and healthcare publications

increased in importance, *European Hospital* is launching a new, online newsletter, so you can receive selected medical news directly in your own eaddress! (For subscription details, please visit our website!)

Along with our main medical and healthcare publications and related activities, *European Hospital* is again organising the *Hospital Manager Symposium 2008*, in tandem with the *European Congress of Radiology* (ECR). In 2007, the Symposium attracted over 300 radiologists to hear talks and lectures given by our selected international experts in Finance, IT and Management.

Also, at this year's ECR, we launched our latest publication: The *RADBOOK*, the first guide for radiology equipment in the English language. EH will continue the successful publication of this valuable source of information for those who must make decisions on purchasing new systems for their hospitals and clinics.

We have also expanded our pan-European readership to Russia, by publishing, within our prestigious journal *European Hospital*, several special issues, as well as additional pages in the Russian language – a great success. In addition, we will publish, for the first time, a special issue for the most important Russian medical fair – *Zdravo* (Zdravookhraneniye 2007).

EH special publications in 2007 Special supplements: Mammography. Surgery. Plus: EH@ECR, EH@ ESC, EH@Moscow Medical Fair EH fair activities Europe: MEDICA and the ECR USA: The RSNA, in Chicago.





∞)U†I

Approved

Event





24th KOREA INTERNATIONAL MEDICAL & HOSPITAL EQUIPMENT SHOW

KIMES 2008 will be exhibiting at 36,027m² exhibition space with 1,300 exhibitors from 35 nations, 60,000 visitors 70 countries.

> Medical ideas! For the better life!



2-2 Kudan Kita, 1 Chome Chiyoda-Ku Tokyo 102, Japan Tel: + 81 3 3263 5065, Fax: +81 3 3224 2064 e-mail: ta@european-hospital.com South Korea Far East Marketing Inc,

CH Park, Room 103-1011, Brown Stone, 1330, Baekseok-dong, Ilsan-ku, Goyang-si, Gyunggi-do, Korea 410-360 Tel: +82 2 730 1234, Fax: +82 2 732 8899 e-mail: ch@european-hospital.com

Taiwan

Jurassic Communications Corp., Ben Chen, 10° Floor-4, No 235, Chang Chuen Road, Taipei 10479, Taiwan R.O.C., Tel: +886 2 2503 8028, Fax: +886 2 2503 2385 e-mail: bc@european-hospital.com

USA & Canada

Media International, Hanna Politis, 8508 Plum Creek Drive, Gaitherburg, MD 20882, USA Tel: +1 301 8696 610, Fax: +1 301 8696 611 email: hp@european-hospital.com

2007@MEDICA

Our other publications

14 15 16

March

ORGANIZERS

Korea E & Ex Inc. Korea Medical Devices Industrial Coop. Association Korea Medical Devices Industry Association

CONTACT : Korea E & Ex Inc.

Rm.2001, KWTC, 159-1, Samsung-dong, Gangnam-gu, Seoul 135-729, Korea Tel. +82-2-551-0102 / Fax. +82-2-551-0103 / E-mail. kimes@kimes.kr

www.kimes.kr

COEX Seoul Korea



Individual quality, collective brilliance.



UP-D897



DXC-C33P



PDW-70MD



LMD-2450MD



SONY

Sony's pioneering innovations in future-proof technology give today's healthcare professionals a range of medical imaging devices that delivers not just outstanding individual quality, but also collective brilliance. From dedicated, High Definition medical monitors and recorders, to cameras, radiology imagers and printers – for the clearest picture, make sure it's a Sony. **Visit us at MEDICA 2007 - Stand A21 in Hall 15**.

www.sonybiz.net/medicahd